Biogen MS Drug Shows Some Promise in Repairing Eye Nerve Damage

January 8, 2015 1:36 PM

16 0

Biogen Idec Inc. (BIIB:US)’s experimental drug for multiple sclerosis showed signs that it could help repair nerve damage in patients’ eyes, a tentatively positive step for a drug aimed at reversing progression of the disease.

In a mid-stage trial of 82 patients, Biogen’s drug showed a 34 percent improvement in those who completed the study. The result fell a hair below the threshold for statistical significance. Including patients who didn’t complete the study, results were positive but didn’t reach statistical significa...

Read more

To category page